María J. Paniagua Martín-rekin lankidetzan egindako argitalpenak (6)

2019

  1. Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world

    European Journal of Heart Failure, Vol. 21, Núm. 11, pp. 1383-1397

2018

  1. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry

    JACC: Heart Failure, Vol. 6, Núm. 6, pp. 452-462

2014

  1. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: Calcineurin-inhibitors conversion or minimization?

    International Journal of Cardiology, Vol. 171, Núm. 1, pp. 15-23

2013

  1. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry

    European Journal of Heart Failure, Vol. 15, Núm. 10, pp. 1173-1184

  2. Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation

    Clinical Transplantation, Vol. 27, Núm. 6

2012

  1. Steroid Withdrawal during 5 years following heart transplantation, and the relationship between steroid dosage at 1-year follow-up and complications during the next 2 years: Results from the restco study

    Transplantation Proceedings